# Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/oral-thin-film-cannabinoid-delivery-quickstrip-platform/ > **Published:** 2026-02-23T17:36:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:14:30-04:00 > **Clinical Summary:** Explore oral thin film cannabinoid delivery with QuickStrip's platform offering rapid onset and precise dosing for cannabis medicine. --- CED Clinical Relevance #52 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. DosingResearchIndustrySafetyAging Why This Matters If oral thin film cannabinoid delivery becomes clinically available, patients who struggle with inconsistent edible absorption or who cannot inhale may gain access to a faster-acting, more precisely dosed alternative. Clinical Summary Oral thin film delivery systems for cannabinoids represent an evolving area of drug delivery research that could address some of the longstanding challenges in cannabis medicine, including inconsistent absorption, delayed onset, and difficulty achieving precise dosing. From a clinical perspective, sublingual and buccal delivery methods bypass first-pass hepatic metabolism, potentially offering more predictable pharmacokinetics compared to traditional edibles while providing a smoke-free alternative for patients who need rapid onset without inhalation. The advancement of standardized delivery platforms like dissolvable strips could be particularly meaningful for patients who struggle with conventional dosing methods, including elderly patients and those with swallowing difficulties. Dr. Caplan’s Take β€œWe have needed better delivery technology in cannabis medicine for years because the gap between what patients need pharmacologically and what the market actually offers has been one of the biggest barriers to consistent clinical outcomes.” Clinical Perspective Oral thin film technology for cannabinoids addresses one of the most frustrating gaps in cannabis medicine: the inability to deliver consistent, predictable doses through a patient-friendly format. Sublingual and buccal delivery bypasses first-pass metabolism, which is why so many patients report wildly different experiences with edibles but more consistency with sublingual tinctures. For my elderly patients and those with dysphagia or nausea, a dissolvable strip could be genuinely transformative compared to capsules or oils they struggle to take. The real clinical win here is not novelty but reproducibility, because we cannot practice [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) medicine if every dose is a pharmacokinetic coin flip. I will be watching the clinical data closely because the delivery method is only as good as the outcomes it produces in real patients. Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Rapid+Dose+Therapeutics+Advances+%3Cb%3ECannabinoid%3C%2Fb%3E+Studies+for+QuickStrip+Drug+Delivery+Platform+%40drcaplan&url=https%3A%2F%2Fwww.tipranks.com%2Fnews%2Fcompany-announcements%2Frapid-dose-therapeutics-advances-cannabinoid-studies-for-quickstrip-drug-delivery-platform) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.tipranks.com%2Fnews%2Fcompany-announcements%2Frapid-dose-therapeutics-advances-cannabinoid-studies-for-quickstrip-drug-delivery-platform) [πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Rapid+Dose+Therapeutics+Advances+%3Cb%3ECannabinoid%3C%2Fb%3E+Studies+for+QuickStrip+Drug+Delivery+Platform+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.tipranks.com%2Fnews%2Fcompany-announcements%2Frapid-dose-therapeutics-advances-cannabinoid-studies-for-quickstrip-drug-delivery-platform) [πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [πŸ“ Read more on Substack](https://substack.com/@doctorapproved) [πŸ”” Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) πŸ“° Source: [https://www.tipranks.com/news/company-announcements/rapid-dose-therapeutics-advances-cannabinoid-studies-for-quickstrip-drug-delivery-platform](https://www.tipranks.com/news/company-announcements/rapid-dose-therapeutics-advances-cannabinoid-studies-for-quickstrip-drug-delivery-platform) Further Reading Evidence Watch[Regulatory Digest 2026-03-08](https://cedclinic.com/regulatory-digest-2026-03-09/)Cannabis Memes[College is hard lmao](https://cedclinic.com/college-is-hard-lmao/)CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Curaleaf Laboratories becomes first UK manufacturer of medical cannabis suppositories](https://cedclinic.com/curaleaf-laboratories-becomes-first-uk-manufacturer-of-medical-cannabis-suppositories/) Discover how Curaleaf Laboratories is innovating [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) delivery with suppositories, expanding patient options. [Learn More](https://cedclinic.com/curaleaf-laboratories-becomes-first-uk-manufacturer-of-medical-cannabis-suppositories/) [The Best CBD for Immune Support and Daily Resilience in 2026](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Explore top [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) that support immune health and daily resilience, backed by current research. [Explore CBD Options](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) [The Best CBD for Mental Clarity and Focus in 2026](https://cedclinic.com/best-cbd-for-mental-clarity-2026-focus-stupiddope/) Learn about CBD formulations that enhance mental clarity and focus, supported by recent studies. [Discover More](https://cedclinic.com/best-cbd-for-mental-clarity-2026-focus-stupiddope/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).